HS Code:
4-Propylbenzaldehyde (CAS No. 28785-06-0) is an organic compound classified under HS Code 2912.29.60, which pertains to cyclic aldehydes without other oxygen function. It is primarily used as an intermediate in the synthesis of pharmaceuticals, fragrances, and other fine chemicals. This compound is part of the broader aldehyde category, which plays a significant role in industrial applications due to its reactivity and versatility in chemical synthesis.
Total Trade Volume
Approximately $12.5 million USD
Data from 2022
Source
United Nations Comtrade Database and industry reports
$5.2 million USD
41.6% of total trade of total trade
Increasing
$2.8 million USD
22.4% of total trade of total trade
Stable
$1.9 million USD
15.2% of total trade of total trade
Increasing
$1.1 million USD
8.8% of total trade of total trade
Increasing
$0.8 million USD
6.4% of total trade of total trade
Stable
Average Rate
5.5% ad valorem
Highest Rate
10% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements like USMCA and EU-Japan EPA)
Growing demand in pharmaceutical intermediates
Increased production and trade volume, especially in Asia-Pacific regions, due to rising generic drug manufacturing
2021-2022
Shift towards sustainable chemical synthesis
Pressure on manufacturers to adopt greener production methods, potentially increasing costs but also opening new markets in eco-conscious regions
2022
Supply chain disruptions due to geopolitical tensions
Temporary shortages and price volatility in key markets, prompting diversification of supply sources
2022
A leading chemical manufacturer in China announced the opening of a new production facility for specialty aldehydes, including 4-Propylbenzaldehyde, to meet rising global demand.
March 2023
Expected to increase China's export capacity by 15%, potentially lowering global prices in the short term.
The European Union updated its REACH regulations, imposing stricter guidelines on the import and use of cyclic aldehydes, including mandatory environmental impact assessments.
January 2023
May lead to higher compliance costs for exporters to the EU, potentially reducing trade volume from non-compliant regions.
The United States extended tariff waivers on certain chemical intermediates, including products under HS 2912.29.60, to support domestic pharmaceutical production.
June 2023
Likely to boost imports from key trading partners like China and India, fostering trade growth.